Discover how intelligent protection relays are evolving beyond fault detection to deliver real-time insights, power quality ...

Novo Nordisk’s weight-loss drug CagriSema failed to meet a critical goal in late-stage clinical trials. This shortcoming bodes well for pharmaceutical companies working on similar obesity treatments.

Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly’s obesity blockbuster Zepbound in a phase 3 weight loss study, further denting the Danish pharma’s attempts to reclaim its obesity crown.

Under the efficacy estimand, patients treated with CagriSema achieved a 23.0% weight loss compared with 25.5% in those treated with tirzepatide. Topline results were ...

SACRAMENTO, Calif., Feb. 19, 2026 /PRNewswire/ -- KilgourMD, the dermatologist-founded scalp health and hair growth brand, created by Stanford-trained board-certified dermatologist Dr. James Kilgour, ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 Advancing NA-931, the first oral quadruple receptor ...

BAODING, HEBEI, CHINA, January 16, 2026 /EINPresswire.com/ — In the critical field of electrical maintenance and safety, the reliability of testing equipment ...

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo. Reading time 2 minutes The competition to develop the next ...

SPOKANE, Wash. — Spokane Mayor Lisa Brown and community leaders are expressing concern as the Temporary Protection Status (TPS) for hundreds of thousands of Haitian nationals in the U.S., including ...

Patients in a phase 2b trial kept losing weight after switching to monthly dosing of Pfizer’s GLP-1 receptor agonist, providing early validation of the drugmaker’s $10 billion bet on Metsera. The ...